Crohn's disease - infliximab (review) and adalimumab (review of TA40) (TA187)
Fast, easy summary view of NICE guidance on 'crohn's disease'
Use of tumour necrosis factor alpha (TNF a) inhibitors (adalimumab, and infliximab [review]) for Crohn's disease (review of TA40)
This guidance replaces 'NICE technology appraisal guidance 40' issued in April 2002.
The review and re-appraisal of infliximab for the treatment of severe active or active fistulising Crohn’s disease has resulted in a change in the guidance. Specifically, infliximab should now be given as a planned course of treatment until treatment failure (including the need for surgery) or for 12 months, whichever is shorter. Treatment should then only be continued if there is clear evidence of ongoing active disease. Adalimumab is now also recommended as another treatment option for people with severe active Crohn’s disease.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: crohn's disease
This page was last updated: 05 October 2012
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA187 Infliximab ac adalimumab ar gyfer afiechyd Crohn: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
- Audit support
- Costing template
- Biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology commissioning guide
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.